Low-Dose Naltrexone for Older Adults (65+): Caregiver Administration Guidance

What the naltrexone labels cover, and what they do not

Naltrexone hydrochloride 50 mg tablets are FDA-approved for alcohol dependence and for blockade of the effects of exogenously administered opioids [2]. Vivitrol, a 380 mg extended-release injection given every four weeks, is approved for alcohol dependence in patients who can abstain before starting and for prevention of relapse to opioid dependence after detoxification [1]. Both are prescription products with labels written for those specific doses and forms [2][1].

Low-dose naltrexone is not an FDA-approved product or indication [3]. It means naltrexone at doses far below 50 mg, typically 0.5 to 6 mg per day and most often 4.5 mg per day, used off-label and commonly prepared by compounding pharmacies [3]. The dosage sections of the naltrexone labels describe 50 mg tablets and 380 mg injections; they do not describe LDN doses [2][1].

For a caregiver, this means the label dosing schedules, warning sections and adverse reaction tables belong to those two products. FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [4].

A 2026 narrative review screened 105 LDN studies, including 15 randomized trials, and concluded that current evidence does not support routine clinical use [3]. The same review describes LDN as generally safe and well tolerated but unproven, with early positive findings rarely confirmed in placebo-controlled trials [3]. Proposed mechanisms such as TLR4 antagonism remain largely theoretical and speculative [3].

The opioid rule is the one firm administration issue

Naltrexone is a pure opioid antagonist that blocks opioid effects by competitive binding at opioid receptors [2]. The tablet and injection labels contraindicate naltrexone in patients receiving opioid analgesics and in patients currently dependent on opioids, including those maintained on methadone or buprenorphine [2][1]. Patients in acute opioid withdrawal, or with a positive urine screen for opioids, are also excluded [2][1]. The contraindication for people receiving opioid analgesics is written without any dose exception [2].

The tablet label recommends an opioid-free interval of at least 7 to 10 days for patients previously dependent on short-acting opioids, and includes tramadol among the opioids that must be cleared [2]. Patients switching from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [2]. A naloxone challenge test may help but is not completely reliable [2].

Opioid-containing cough and cold products and antidiarrheal products also count, because naltrexone antagonizes them and the patient may not benefit [2]. The label says that in an emergency needing opioid analgesia, the amount of opioid required may be greater than usual and respiratory depression may be deeper and more prolonged [2].

What is known about older adults

One 2024 fibromyalgia trial enrolled women aged 18 to 64 [5]. The 2026 review of 105 studies does not support routine use and calls for larger trials with objective endpoints [3].

The Vivitrol label has a geriatric statement; no LDN label exists. It says no subjects over age 65 were included in studies of opioid-dependent subjects, that Vivitrol pharmacokinetics have not been evaluated in the geriatric population, and that elderly patients are more likely to have decreased renal function, so it may be useful to monitor renal function [1]. That is a statement about the 380 mg injection, not about compounded LDN.

The LDN evidence itself is mixed. A small crossover trial of 31 women with fibromyalgia found a 28.8% reduction in pain with 4.5 mg naltrexone daily versus 18.0% with placebo [6]. Later, larger placebo-controlled trials did not beat placebo on their main pain outcomes: 58 patients [7], 98 patients [8] and 99 patients [5]. A meta-analysis of 4 trials and 222 patients found a small pain score difference favoring LDN, mean difference -0.86, but no significant difference in the revised fibromyalgia impact questionnaire [9]. That is a modest, uncertain signal, not a proven geriatric treatment.

Dose, timing and what a caregiver can record

No LDN dosing schedule has been established specifically for adults 65 and older. LDN is prescribed off-label at 0.5 to 6 mg per day, most often 4.5 mg, and the 2026 review calls the 4.5 mg dose 'empirically derived rather than evidence-based' [3].

A simple daily record can include the dose and time given, sleep quality, vivid or distressing dreams, nausea, dizziness, appetite and any new confusion or unsteadiness. The LDN trials most often report insomnia, vivid dreams, nausea and dizziness, usually mild and transient [3]. A meta-analysis found more vivid dreams and nausea with LDN than placebo, with no significant difference in serious adverse events [9].

The 12-month INNOVA trial in 98 women with fibromyalgia reported adverse events in 68.8% of those on LDN and 72% of those on placebo, with no treatment-related serious events [8].

What the labels say about liver and allergy warnings

The current 50 mg tablet label has no boxed warning [2]. It describes cases of hepatitis and clinically significant liver dysfunction in development and postmarketing, and says placebo-controlled studies using up to 300 mg per day, five times the recommended dose, showed hepatocellular injury in a substantial proportion of patients at higher doses [2]. The Vivitrol label reports AST elevations in short-term alcohol-dependence trials of 1.5% with Vivitrol and 1.5% with oral naltrexone versus 0.9% with placebo [1]. Those are 50 mg and 380 mg data; the labels give no guidance on LDN doses.

Hypersensitivity to naltrexone or a product component is a contraindication for the tablet [2]. The Vivitrol label lists urticaria, angioedema and anaphylaxis among hypersensitivity reactions [1]. Those are injection-label events and are not a substitute for an LDN safety profile.

Compounded product checks

Because LDN is compounded, the 2026 review notes that inconsistencies in compounded formulations add uncertainty [3]. FDA says poor compounding practices can cause serious quality problems, including contamination or a drug that contains too much or too little active ingredient [4]. Naltrexone is not named on FDA's page of bulk drug substances that raise significant safety risks [10].

A 2025 study of a compounded naltrexone 1 mg/mL suspension in one specific vehicle found pH and appearance stable at ambient and refrigerated storage, and storage temperature did not significantly affect stability [11]. That covers one formulation, not every compounded LDN capsule or liquid.

Compounding can also make a liquid for a patient who cannot swallow a tablet or capsule [4]. HealthRX.com offers low-dose naltrexone by prescription.

When the label points to emergency care

The main emergency picture in the tablet label is precipitated withdrawal after naltrexone in someone who may have opioids in their system. Symptoms usually appeared within 5 minutes of ingestion and lasted up to 48 hours; confusion, somnolence, visual hallucinations, and fluid losses from vomiting and diarrhea needing intravenous fluids occurred, and postmarketing cases required hospital admission and sometimes intensive care [2].

The labels also warn that opioid tolerance falls after treatment stops, at the end of a dosing interval, or after a missed dose, and that fatal overdoses have been reported [2][1]. The labels say patients and caregivers should be told about opioid overdose reversal agents such as naloxone or nalmefene, and that prescribers should strongly consider prescribing one when starting and renewing treatment [2][1]. The Vivitrol label says to call 911 or get emergency medical help in all cases of known or suspected opioid overdose, even if a reversal agent is given [1].